Changeflow GovPing Pharma & Drug Safety Plasma Protein Treatment Methods
Routine Notice Added Final

Plasma Protein Treatment Methods

Favicon for changeflow.com EPO Patent Bulletin - Peptides (C07K)
Published
Detected
Email

Summary

The European Patent Office published patent application EP4153236A1, granting protection for methods of treating plasma protein imbalances or depletion to Ohio State Innovation Foundation and The Regents of the University of California. The patent covers therapeutic compositions and methods using specified compounds for treating conditions including hemorrhage, hypovolemia, and shock.

What changed

The EPO published patent EP4153236A1 for methods treating plasma protein imbalances or depletion, filed by Ohio State Innovation Foundation and The Regents of the University of California. The patent covers therapeutic methods using plasma protein compositions and related compounds, classified across multiple IPC categories including A61K, C07K, and A61P codes.

For pharmaceutical and biotechnology companies developing plasma protein therapies or blood substitutes, this patent establishes IP protection in European markets across 31 designated states. Parties operating in the hemotherapy, fluid resuscitation, or critical care sectors should assess freedom-to-operate implications for related product development in EU jurisdictions.

What to do next

  1. Monitor for updates

Archived snapshot

Apr 10, 2026

GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.

← EPO Patent Bulletin

METHODS FOR TREATING PLASMA PROTEIN IMBALANCES OR DEPLETION

Publication EP4153236A1 Kind: A1 Apr 01, 2026

Applicants

Ohio State Innovation Foundation, The Regents of the University of California

Inventors

SUSIN PIRES, Ivan, PALMER, Andre, CABRALES AREVALO, Pedro J.

IPC Classifications

A61K 31/555 20060101AFI20240523BHEP A61K 31/195 20060101ALI20240523BHEP A61K 35/16 20150101ALI20240523BHEP A61K 38/17 20060101ALI20240523BHEP A61K 38/40 20060101ALI20240523BHEP A61K 38/38 20060101ALI20240523BHEP A61K 39/395 20060101ALI20240523BHEP A61K 45/06 20060101ALI20240523BHEP C07K 16/28 20060101ALI20240523BHEP A61P 7/08 20060101ALI20240523BHEP A61P 9/00 20060101ALI20240523BHEP

Designated States

AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR

View original document →

Get daily alerts for EPO Patent Bulletin - Peptides (C07K)

Daily digest delivered to your inbox.

Free. Unsubscribe anytime.

About this page

What is GovPing?

Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission

What's from the agency?

Source document text, dates, docket IDs, and authority are extracted directly from EPO.

What's AI-generated?

The plain-English summary, classification, and "what to do next" steps are AI-generated from the original text. Cite the source document, not the AI analysis.

Last updated

Classification

Agency
EPO
Published
April 1st, 2026
Instrument
Notice
Legal weight
Binding
Stage
Final
Change scope
Minor
Document ID
EP4153236A1

Who this affects

Applies to
Pharmaceutical companies Manufacturers
Industry sector
3254 Pharmaceutical Manufacturing
Activity scope
Patent issuance Therapeutic method development
Geographic scope
European Union EU

Taxonomy

Primary area
Intellectual Property
Operational domain
Legal
Topics
Pharmaceuticals Healthcare

Get alerts for this source

We'll email you when EPO Patent Bulletin - Peptides (C07K) publishes new changes.

Free. Unsubscribe anytime.

You're subscribed!